Tesamorelin: Research Chemistry and Literature

Origin and identification

Growth hormone releasing hormone itself was not in hand until 1982. Rivier, Spiess, Thorner and Vale isolated the releasing factor from a human pancreatic islet tumour and reported both the 44 residue amidated form and a 40 residue variant in Nature. The tumour source mattered. Hypothalamic tissue holds the peptide in quantities too small for the isolation chemistry of the period, and the ectopic source supplied enough material to finish the sequence.

Tesamorelin was developed later under the code TH9507. The design brief was stability rather than affinity. Attaching a six carbon hexenoyl side chain to the N-terminal tyrosine blocks the aminopeptidase route that limits the native molecule and leaves the receptor-binding helix untouched. Published work on the compound begins in the preclinical literature. A 2004 study in the dog reported its pharmacokinetic behaviour, and a 2007 non-clinical pharmacology package extended the work across pig, rat and dog, with plasma degradation measured in vitro for each species.

Preclinical research context

The receptor is GHRHR, a class B G protein coupled receptor expressed on pituitary somatotrophs. Zhou and colleagues published a cryo-electron microscopy structure of the human receptor bound to its endogenous ligand and the stimulatory G protein at 2.6 angstrom resolution in 2020. The helical ligand contacts the extracellular domain, every extracellular loop and most of the transmembrane bundle. Because tesamorelin retains the complete 1-44 sequence, that structure is the usual frame of reference when its receptor engagement is discussed.

Bench pharmacology for this class runs on cyclic AMP accumulation in cell lines expressing recombinant human GHRHR, and on radioligand competition against pituitary membrane preparations. Primary rat anterior pituitary cell culture remains the classical functional system, with secreted growth hormone quantified by immunoassay from the culture medium. Comparative incubation in species plasma separates intrinsic potency from proteolytic loss, which is the axis along which acylated GHRH analogues were designed in the first place.

The in vivo record is confined to pig, Sprague-Dawley rat and dog, with circulating growth hormone and insulin-like growth factor 1 as the biochemical readouts and subchronic observation running to four months. The compound also recurs throughout sports drug testing method development, where the analytical problem is detecting an intact 44 residue peptide and its N-terminal fragments in a complex biological matrix. That body of work is a useful source of validated chromatographic and spectrometric conditions.

Analytical characterisation

Purity is determined by reverse-phase HPLC. A C18 stationary phase with a water and acetonitrile gradient in dilute trifluoroacetic acid resolves the main peak from the impurities that matter, which for a chain of this length are truncated sequences from incomplete couplings, deamidation products at the asparagine and glutamine positions, and residual acetylated fragments. Area percent at 214 nanometres reports the backbone rather than any single side chain, and is the figure quoted as peptide purity.

Identity is settled by mass spectrometry. Electrospray ionisation of a peptide near five kilodaltons produces a multiply charged envelope, and deconvolution returns an average mass compared against the value calculated for the hexenoylated 44 residue amide. The acyl modification adds 96 mass units, so high resolution instruments separate modified from unmodified sequence directly, and enzymatic digestion followed by peptide mapping localises the group to the N-terminal fragment. Certificates of Analysis for material listed here are produced by Janoshik Analytical and report identity, chromatographic purity and net peptide content per lot, the last being the number that distinguishes peptide mass from counterion and residual water.

Handling and storage

Lyophilised tesamorelin tolerates ambient temperature for the length of ordinary shipping, which is why vials arrive without a cold chain. On receipt, move the sealed vial to minus 20 degrees Celsius. Keep it dark. Methionine 27 is the one residue that oxidises on standing, and light exposure drives that pathway harder than storage temperature does.

Reconstituted material is a different proposition. Once in aqueous solution the peptide should be held at 2 to 8 degrees Celsius and treated as short-lived. Solution stability, not the stability of the solid, sets the working window. Prepare only what a session requires and record the date the vial was opened.

Avoid repeated freeze-thaw. Each cycle concentrates solute at the advancing ice front and drives aggregation and surface adsorption, and the losses accumulate without being visible. Divide into single-use aliquots at the point of reconstitution, freeze them once, and thaw each one only when it is about to be used.

References

1. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour
2. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue
3. Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog
4. Structural basis for activation of the growth hormone-releasing hormone receptor
5. Advances in the detection of growth hormone releasing hormone synthetic analogs
6. Tesamorelin, PubChem Compound Summary CID 16137828

Related compounds